Argos Therapeutics, Inc.
ARGS
ARGS was delisted on the 24th of April, 2018.
52 hedge funds and large institutions have $102M invested in Argos Therapeutics, Inc. in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 9 reducing their positions, and 2 closing their positions.
13,977% more call options, than puts
Call options by funds: $28.6M | Put options by funds: $203K
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
226% more capital invested
Capital invested by funds: $31.3M → $102M (+$70.8M)
156% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 9
13% more funds holding
Funds holding: 46 → 52 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$4.79M |
| 2 |
Millennium Management
New York
|
+$560K |
| 3 |
California Public Employees Retirement System
Sacramento,
California
|
+$443K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$282K |
| 5 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$239K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$521K |
| 2 |
WSA
Wall Street Associates
Lajolla,
California
|
-$478K |
| 3 |
Morgan Stanley
New York
|
-$119K |
| 4 |
DTL
Dynamic Technology Lab
Singapore
|
-$94K |
| 5 |
Goldman Sachs
New York
|
-$64.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
BNP Paribas Financial Markets
Paris,
France
| $985 | -$3.37K | -36 | -78% |
|
|
52
Alyeska Investment Group
Chicago,
Illinois
| – | -$521K | -5,571 | Closed |
|
|
DTL
53
Dynamic Technology Lab
Singapore
| – | -$94K | -950 | Closed |
|
|
CG
54
Cutler Group
San Francisco,
California
| – | -$7.95K | -85 | -94% |
|
ARGS Hedge Fund Activity: Q4 2016 in Review
52 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Argos Therapeutics, Inc. (ARGS) for Q4 2016, worth a combined $102M — up 226% from $31.3M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ARGS positions and 2 closed out — a net gain of 6 holders — while 23 added to existing stakes and 9 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $4.79M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $521K sold.
- 52 institutional investors held Argos Therapeutics, Inc. (ARGS) as of Q4 2016, up from 46 in Q3 2016.
- Funds reported $102M of Argos Therapeutics, Inc. stock for Q4 2016, up 226% quarter-over-quarter.
- 8 funds opened new Argos Therapeutics, Inc. positions in Q4 2016 and 2 closed out, a net change of +6 holders.
- The largest Argos Therapeutics, Inc. buyer in Q4 2016 was Susquehanna International Group, an estimated $4.79M added.
- The largest Argos Therapeutics, Inc. seller in Q4 2016 was Alyeska Investment Group, an estimated $521K sold.
Based on aggregated 13F filings for Q4 2016.